238 related articles for article (PubMed ID: 15346332)
1. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.
Quinn CP; Dull PM; Semenova V; Li H; Crotty S; Taylor TH; Steward-Clark E; Stamey KL; Schmidt DS; Stinson KW; Freeman AE; Elie CM; Martin SK; Greene C; Aubert RD; Glidewell J; Perkins BA; Ahmed R; Stephens DS
J Infect Dis; 2004 Oct; 190(7):1228-36. PubMed ID: 15346332
[TBL] [Abstract][Full Text] [Related]
2. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
[TBL] [Abstract][Full Text] [Related]
3. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
4. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
Semenova VA; Schmidt DS; Taylor TH; Li H; Steward-Clark E; Soroka SD; Ballard MM; Quinn CP
Vaccine; 2007 Feb; 25(10):1780-8. PubMed ID: 17229495
[TBL] [Abstract][Full Text] [Related]
5. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.
Quinn CP; Semenova VA; Elie CM; Romero-Steiner S; Greene C; Li H; Stamey K; Steward-Clark E; Schmidt DS; Mothershed E; Pruckler J; Schwartz S; Benson RF; Helsel LO; Holder PF; Johnson SE; Kellum M; Messmer T; Thacker WL; Besser L; Plikaytis BD; Taylor TH; Freeman AE; Wallace KJ; Dull P; Sejvar J; Bruce E; Moreno R; Schuchat A; Lingappa JR; Martin SK; Walls J; Bronsdon M; Carlone GM; Bajani-Ari M; Ashford DA; Stephens DS; Perkins BA
Emerg Infect Dis; 2002 Oct; 8(10):1103-10. PubMed ID: 12396924
[TBL] [Abstract][Full Text] [Related]
6. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
[TBL] [Abstract][Full Text] [Related]
7. No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001.
Baggett HC; Rhodes JC; Fridkin SK; Quinn CP; Hageman JC; Friedman CR; Dykewicz CA; Semenova VA; Romero-Steiner S; Elie CM; Jernigan JA
Clin Infect Dis; 2005 Oct; 41(7):991-7. PubMed ID: 16142664
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
[TBL] [Abstract][Full Text] [Related]
9. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
Lininger LA; Cullum ME; Lyles MB; Bienek DR
Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286
[TBL] [Abstract][Full Text] [Related]
10. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
Pittman PR; Fisher D; Quinn X; Schmader T; Barrera-Oro JG
Vaccine; 2013 Oct; 31(44):5009-14. PubMed ID: 24026013
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of an anthrax DNA vaccine with electroporation.
Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
[TBL] [Abstract][Full Text] [Related]
12. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG.
Semenova VA; Schiffer J; Steward-Clark E; Soroka S; Schmidt DS; Brawner MM; Lyde F; Thompson R; Brown N; Foster L; Fox S; Patel N; Freeman AE; Quinn CP
J Immunol Methods; 2012 Feb; 376(1-2):97-107. PubMed ID: 22197974
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
Sloat BR; Cui Z
J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
[TBL] [Abstract][Full Text] [Related]
14. Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes.
Ingram RJ; Metan G; Maillere B; Doganay M; Ozkul Y; Kim LU; Baillie L; Dyson H; Williamson ED; Chu KK; Ascough S; Moore S; Huwar TB; Robinson JH; Sriskandan S; Altmann DM
J Immunol; 2010 Apr; 184(7):3814-21. PubMed ID: 20208010
[TBL] [Abstract][Full Text] [Related]
15. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
[TBL] [Abstract][Full Text] [Related]
16. Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody.
Kasuya K; Boyer JL; Tan Y; Alipui DO; Hackett NR; Crystal RG
Mol Ther; 2005 Feb; 11(2):237-44. PubMed ID: 15668135
[TBL] [Abstract][Full Text] [Related]
17. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.
Pittman PR; Norris SL; Barrera Oro JG; Bedwell D; Cannon TL; McKee KT
Vaccine; 2006 Apr; 24(17):3654-60. PubMed ID: 16497418
[TBL] [Abstract][Full Text] [Related]
18. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
Brenneman KE; Doganay M; Akmal A; Goldman S; Galloway DR; Mateczun AJ; Cross AS; Baillie LW
FEMS Immunol Med Microbiol; 2011 Jul; 62(2):164-72. PubMed ID: 21401726
[TBL] [Abstract][Full Text] [Related]
19. Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine.
Bienek DR; Chang CK; Cohen ME
Vaccine; 2007 Aug; 25(32):5978-84. PubMed ID: 17597265
[TBL] [Abstract][Full Text] [Related]
20. Generation of mouse polyclonal and human monoclonal antibodies against Bacillus anthracis toxin.
Huber M; Vor Dem Esche U; Grunow R; Bessler WG
Drugs Exp Clin Res; 2005; 31(2):35-43. PubMed ID: 15929604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
